As part of the 20th Meeting of the European Association for Haematopathology virtual event, Thermo Fisher Scientific hosted an educational industry symposium focused on the uses of next-generation sequencing (NGS) in lymphoid research.
Next-generation sequencing (NGS) is increasingly being adopted for BCR and TCR sequence analysis, as well as targeted gene panels in lymphoma research. NGS has advantages over other more traditional approaches as it provides low limits of detection (LOD), and a greater flexibility to multiplex.
In this on-demand presentation, lab directors share their insights and experience on the value of NGS in their research.
Head of Cytogenetics and Molecular Haematology | Barts Health NHS Trust
Marianne Grantham presents an educational talk on current research on profiling lymphoma samples, the different requirements for different disease types and the benefits of using Next Generation Sequencing for this purpose.
Head of Molecular Pathology | Charité – Universitätsmedizin Berlin
Michael Hummel presents the background and history of clonality testing in Lymphomas and how NGS can improve on more traditional methods. With early access data from our yet to launch Ion Torrent ™ Oncomine ™ Pan-clonality BCR assay, he illustrates his points on the benefits and why laboratories should move the NGS based testing.
Head Department Molecular Diagnostics | Holy Cross Cancer Center
Artur Kowalik presents his work on Multiple Myeloma and the value of NGS for detecting rare clones and the ability to track these clones at different stages of disease. He presents early access data from our yet to launch Ion Torrent ™ Oncomine ™ Pan-clonality BCR assay.
Ask our NGS experts any questions or subscribe to get helpful updates from our team, including whitepapers, webinars, videos, case studies and more!